Curetis Provides Business and Financial Update for the First Quarter 2017
(Thomson Reuters ONE) -
Curetis /
Curetis Provides Business and Financial Update for the First Quarter 2017
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Curetis Provides Business and Financial Update for the First Quarter 2017
- First quarter 2017 revenue increases 2.6-fold year over year
- Successful completion of CE performance evaluation study and launch of Unyvero
IAI Intra-Abdominal Infections (IAI) Cartridge
- Incorporation of wholly-owned subsidiary Ares Genetics to accelerate
commercialization of GEAR database
Amsterdam, the Netherlands, and Holzgerlingen, Germany, May 24, 2017 - Curetis
N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of
next-level molecular diagnostic solutions, today published a business and
financial update for the first quarter ended March 31, 2017, and provided
details on its outlook for the remainder of the year.
Recent Operational and Business Highlights
Unyvero U.S. FDA Trials
* In January 2017, Curetis filed a 510(k) application with the U.S. Food and
Drug Administration (FDA) to obtain clearance for its Unyvero Platform and
LRT Application Cartridge. The submission is based on clinical data from the
Company's U.S. FDA trial comparing the performance of the Unyvero LRT Lower
Respiratory Tract Cartridge in detecting respiratory pathogens to
microbiology culture, the current diagnostic standard of care.
* In March 2017, Curetis received a letter from the FDA requesting additional
details on pathogens, antibiotic resistance markers, sample types etc. To
clarify the remaining open issues, a so-called `Submissions Issues` meeting
was held on April 21, 2017. Following this meeting, Curetis has submitted
draft minutes to the FDA, continues to respond to the Agency's requests
during interactive review, and expects to provide complete responses on
remaining open items in the coming months. Curetis expects a clearance
decision from the FDA in the second half of 2017.
* In addition, Curetis continues to prepare for its second FDA trial with the
goal of clearing the second Unyvero Cartridge in the U.S. This Unyvero
Cartridge is expected to be a U.S. version of the Unyvero Implant and Tissue
Infection (ITI) Cartridge, which is tailored to specific U.S. customer and
market needs and focuses on (prosthetic) joint infections (PJI).
* Curetis has recently successfully completed a clinical feasibility study for
the U.S. version of the PJI / ITI panel. Having run over 80 synovial fluid
patient samples with available clinical microbiology data, the overall
weighted average sensitivity after discrepant result resolution was 93.5% at
an overall weighted average specificity of 99.8%. The panel identified
several anaerobic pathogens otherwise missed by standard of care
microbiology. Next steps will be finalization of specifications for a U.S.
panel of pathogens and resistance markers to be included and the completion
of development. The PJI cartridge is expected to be ready for the start of
clinical trials in the U.S. later this year.
Corporate Growth
* Curetis has established a new wholly-owned subsidiary - Ares Genetics GmbH -
in Vienna, Austria. Ares Genetics was founded to leverage the GEAR GEnetic
Antibiotic Resistance and Susceptibility Database and associated assets
acquired from Siemens in 2016. The Company will use GEAR to investigate the
genetic foundations of antibiotic resistance and to develop and subsequently
commercialize novel approaches to improve the rapid detection of antibiotic
resistance in patients with microbial infections as well as tools to
accelerate antibiotic research.
* Via its subsidiary Ares Genetics, Curetis will use GEAR as a biomarker
engine to rapidly identify potential novel biomarkers, biomarker
combinations, and algorithms predicting antibiotic resistance, as well as
potential novel targets for antimicrobial drugs. In the future, GEAR may
also pave the way towards fully genetic antibiograms and provide a reference
for NGS-based clinical diagnostics.
* Curetis has drawn down a first tranche of EUR 10 million of the non-dilutive
debt financing facility provided through the European Investment Bank (EIB)
in April 2017 to further advance its R&D and product platform.
Product Development
* In April 2017, Curetis successfully completed the CE performance evaluation
study and subsequently launched its Unyvero IAI Intra-Abdominal Infections
(IAI) Cartridge at ECCMID 2017 in Vienna. The CE-IVD marked IAI application
aims to support clinicians in the fast and reliable diagnosis of various
severe conditions related to the intra-abdominal tract, including
peritonitis, cholecystitis and acute pancreatitis. The comprehensive panel
covers up to 130 diagnostic targets, comprising 92 bacteria, 13 fungi, 3
toxins and 22 antibiotic resistance markers. In the prospective multi-center
study, the IAI panel demonstrated 93.8% overall weighted average sensitivity
and 99.7% overall weighted average specificity.
Installed Base
* Curetis' global installed base of Unyvero Analyzers totaled 151 at the end
of the first quarter 2017 (vs. 107 at the end of the first quarter 2016 and
compared to 142 at year-end 2016).
* During the first quarter of 2017, over a dozen new Unyvero Analyzers were
shipped and several Analyzers were brought back in following successful
completion of customer evaluations. Placements were made at key sites in
France and the UK, regions in which the Company has seen increased momentum
since the establishment of dedicated local sales teams in 2016. Several
accounts have been advanced from successful product evaluation to contract
negotiation stage.
* Customers have finalized several studies providing the basis for additional
publications demonstrating the value of Unyvero, further supporting sales
efforts going forward.
* Based on the installed base approaching 160 Unyvero Analyzers during the
course of Q2 with several recent shipments to key sites in the UK, the
Company reiterates its guidance of an expected global installed base of 200
to 240 Unyvero Analyzers by year-end 2017.
Clinical Studies
* Several presentations at ECCMID 2017 demonstrated the advantages of rapid
diagnostic testing with the Unyvero Implant and Tissue Infection Cartridge
(ITI) in Prosthetic Joint Infections, specifically its clinical and health
economic benefits. Rapid testing of sonication fluid from explanted joint
prostheses demonstrated a shortened length of hospital stays and average
savings of EUR 2,040 per patient. In addition, two studies on the first
generation of Unyvero ITI by Charité - University Medicine Berlin showed
that its performance was similar to culture for sonication fluids and
synovial fluids, with the advantages of shorter processing time and full
automation of the Unyvero System. One of the aforementioned studies
calculated the advantage of time-to-result as 5 hours versus 6.8 days.
* Researchers at the Institute of Medical Microbiology, University Hospital
Essen (Essen, Germany), published data on Unyvero P55 concluding that the
"Unyvero Application is a useful diagnostic tool for the early and rapid
detection of pathogens in respiratory specimens". They reported a
significantly higher detection rate when using Unyvero as compared to
culture methods and a considerably reduced time-to-result, from a median of
48h to a median of 7.5 hours. The team has tested the Unyvero P55 Pneumonia
Cartridge in daily clinical routine with 439 respiratory specimens from 342
patients. Results from the European Study were presented during the 5th
Joint Conference of the DGHM & VAAM / VAAM Annual Meeting 2017.
Supervisory and Medical Advisory Boards
* Dr. Nils Clausnitzer has been nominated for Curetis N.V.'s Supervisory
Board. The election for a three-year term is part of the agenda of the
upcoming Annual General Meeting on June 23, 2017. Nils Clausnitzer is Senior
Vice President and President, EMEA-APAC Lab and Distribution Services of VWR
International llc. / VWR GmbH. Furthermore, Dr. Holger Reithinger and Dr.
Rudy Dekeyser will run for re-election for another one-year term.
* Dr. Melissa Miller, Ph.D., Professor of Pathology and Laboratory Medicine
and Director of the Clinical Molecular Microbiology Laboratory at Chapel
Hill School of Medicine at The University of North Carolina, U.S., has
joined Curetis' Medical Advisory Board. Her special research focus is on the
health economic evaluation of new molecular technologies for detecting viral
infections and drug resistant organisms.
Financial Highlights for the First Three Months 2017
* Revenues: EUR 347.2 k (growing 2.6 times vs. EUR 132.8 k in the first
quarter 2016). In general, revenues are expected to remain volatile from
quarter to quarter, as early-stage instrument sales to distribution partners
are unevenly spread throughout the year.
* Expenses: EUR 4.7 million (vs. EUR 3.3 million in the first quarter 2016).
The increase is in line with the operational and organizational growth, and
driven by higher distribution costs as well as G&A costs.
* Gross loss: EUR 175.7 k (vs. EUR 30.1 k in the first quarter 2016).
* Net loss of the period: EUR 4.4 million (vs. EUR 3.2 million in the first
quarter 2016).
* Cash and cash equivalents: EUR 19.3 million (vs. EUR 22.8 million as of
December 31, 2016). Net cash burn in the first quarter 2017 was EUR 3.5
million. In April 2017, the company has drawn down EUR 10.0 million from the
EIB debt financing facility.
Key non-audited financials as of March 31, 2017
+-----------------------------+-----------------------+------------------------+
|Curetis N.V. | | |
+-----------------------------+-----------------------+------------------------+
|consolidated numbers in '000 | | |
|Euros | | |
+-----------------------------+-----------------------+------------------------+
| |For the three months |For the three months |
| |ended March 31, 2017 |ended March 31, 2016 |
+-----------------------------+-----------------------+------------------------+
|Revenues | 347| 133|
+-----------------------------+-----------------------+------------------------+
|Operating loss | (4,303)| (3,125)|
+-----------------------------+-----------------------+------------------------+
|Total comprehensive income | (4,378)| (3,169)|
+-----------------------------+-----------------------+------------------------+
| | | |
+-----------------------------+-----------------------+------------------------+
| |March 31, 2017 |December 31, 2016 |
+-----------------------------+-----------------------+------------------------+
|Cash and cash equivalents | 19,310| 22,832|
+-----------------------------+-----------------------+------------------------+
"During the past several months, we have laid the foundation for accelerating
Curetis' pipeline, further expansion and corporate growth," said Dr. Oliver
Schacht, CEO of Curetis. "The incorporation of Ares Genetics will enable us to
access new market segments in infectious disease testing. The launch of the
Unyvero IAI Cartridge is another key milestone in building a highly attractive,
value generating product portfolio. In addition, we continue to progress with
our U.S. market launch preparations and have successfully completed a clinical
performance evaluation study for the second potential U.S. product in our
pipeline. Following the 510(k) application, we have been in a continuous
dialogue with the U.S. FDA in order to obtain clearance for our Unyvero System
and LRT Application Cartridge."
###
Disclaimer
CAUTION - Investigational device. Limited by Federal (or United States) law to
investigational use. The information contained in this communication does not
constitute nor imply an offer to sell or transfer any product, and no product
based on the Curetis Unyvero technology is currently available for sale in the
United States of America or Canada. The analytical and clinical performance
characteristics of any Curetis Unyvero product which may be sold at some future
point in time in the U.S. have not yet been established.
###
About Curetis
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the
development and commercialization of reliable, fast and cost-effective products
for diagnosing severe infectious diseases. The diagnostic solutions of Curetis
enable rapid multi-parameter pathogen and antibiotic resistance marker detection
in only a few hours, a process that today can take up to days or even weeks with
other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and
Euronext Brussels and private equity funds of over EUR 63.5 million.
Furthermore, Curetis has entered into a debt financing facility with EIB for up
to EUR 25 million. The company is based in Holzgerlingen near Stuttgart,
Germany. Curetis collaborates with Heraeus Medical, pharmaceutical companies,
and has entered into several international distribution agreements covering many
countries across Europe, the Middle East and Asia.
In 2017, Curetis established Ares Genetics GmbH, a wholly-owned subsidiary of
Curetis GmbH in Vienna, Austria. Ares Genetics is dedicated to maximizing the
R&D and related scientific and business opportunities of the GEAR assets
acquired in 2016 for the entire Curetis Group.
For further information, please visit www.curetis.com.
Legal Disclaimer
This document constitutes neither an offer to buy nor to subscribe securities
and neither this document nor any part of it should form the basis of any
investment decision in Curetis.
The information contained in this press release has been carefully prepared.
However, Curetis bears and assumes no liability of whatever kind for the
correctness and completeness of the information provided herein. Curetis does
not assume an obligation of whatever kind to update or correct information
contained in this press release whether as a result of new information, future
events or for other reasons.
This press release includes statements that are, or may be deemed to be,
"forward-looking statements". These forward-looking statements can be identified
by the use of forward-looking terminology, including the terms "believes",
"estimates", "anticipates", "expects", "intends", "may", "will", or "should",
and include statements Curetis makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks and
uncertainties and readers are cautioned that any such forward-looking statements
are not guarantees of future performance. Curetis' actual results may differ
materially from those predicted by the forward-looking statements. Curetis
undertakes no obligation to publicly update or revise forward-looking
statements, except as may be required by law.
Contact details
Curetis
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr(at)curetis.com or ir(at)curetis.com
www.curetis.com - www.unyvero.com
International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info((at))akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group
Lee Roth
lroth(at)theruthgroup.com
Tel. +1 646 536 7012
20170524_Curetis_PR_EN_Q1 2017:
http://hugin.info/171382/R/2107302/800264.pdf
Curetis_Logo:
http://hugin.info/171382/R/2107302/800266.jpg
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Curetis via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 24.05.2017 - 07:37 Uhr
Sprache: Deutsch
News-ID 544231
Anzahl Zeichen: 18655
contact information:
Town:
Holzgerlingen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 268 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Curetis Provides Business and Financial Update for the First Quarter 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
Curetis (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
